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Abstract
Background: Although it has been suggested that a high level of thymidylate synthase (TYMS) gene expression in
malignant tumors is related to reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an
association has been demonstrated in routine clinical samples from patients treated with the drug. The purpose of this
study was to quantitatively assess the impact of TYMS gene expression in tumor cells as a predictor of the efficacy of
pemetrexed therapy in patients with advanced non-small cell lung cancer (NSCLC) treated at our institution.
Methods: Sixty-two NSCLC patients were included in this study: 16 patients received platins-pemetrexed as first-line
NSCLC, and 46 pemetrexed in monotherapy as second- or subsequent-line treatment. Total mRNA was isolated and
the expression of TYMS was analyzed by RT-qPCR. TYMS levels were calibrated against expression in normal lung tissue.
Results: TYMS overexpression was detected in 61 % of patients and low expression in 39 %. The response rate for
patients with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). A
significant benefit was observed in patients with low expression both in time to progression (average TTP = 56 vs.
23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).
Conclusions: TYMS overexpression in tumor cells correlated with a reduced response to pemetrexed-containing
chemotherapy and might be used as a predictive biomarker in advanced NSCLC patients.
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Background
Pemetrexed, an analogue of folic acid (folate), is a folate
antimetabolite agent that shows antitumor activity, inhibit-
ing 3 enzymes involved in de novo purine and pyrimidine
synthesis: thymidylate synthase (TYMS), dihydrofolate re-
ductase, and glycinamide ribonucleotide formyltransferase
[1]. Consequently, pemetrexed inhibits DNA and RNA
biosynthesis. This agent inhibits the cellular growth of a
variety of tumor types and has been approved for non-
small cell lung cancer (NSCLC) at locally advanced and
metastatic stages [2] for first- and second-line therapy.
As pemetrexed inhibits TYMS more effectively than
the rest of the folate-dependent enzymes, most studies
have focused on the effects of pemetrexed on TYMS. In
vitro studies have demonstrated that high baseline ex-
pression levels conferred resistance to pemetrexed [3–5].
Similarly, some clinical studies have associated elevated
TYMS expression levels with poorer chemotherapeutic
response to pemetrexed, including breast cancer [6],
colorectal cancer [7], head and neck cancer [8], and ma-
lignant pleural mesothelioma [9]. In a large phase III
study in advanced-stage NSCLC patients, survival differ-
ences were reported if favor of a cisplatin/pemetrexed
regimen compared to cisplatin/gemcitabine according to
histology [10]. This was explained by a previous paper
showing that the baseline expression of the thymidylate
synthase gene and protein were significantly higher in
squamous cell carcinoma compared with adenocarcin-
oma (P < 0.0001) [11]. According to some published re-
ports, elevated expression of TYMS may be predictive of
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sensitivity to pemetrexed-based chemotherapy. However,
in some cancer types, such as advanced NSCLC, this
point is controversial. For this reason, we evaluated the
relationship between TYMS gene expression and clinical
outcome in a cohort of 62 patients with advanced
NSCLC treated with a pemetrexed-based regimen at our
institution. A quantitative real-time PCR (qPCR) assay
was devised to determine the TYMS gene expression
level. qPCR is suitable for use with mRNA from archived
formalin-fixed, paraffin-embedded (FFPE) samples, as it
amplifies <100-bp amplicons. Additionally, it is faster
and more precise than immunohistochemistry (IHC).
And it has been reported a correlation between TYMS
mRNA levels and protein abundance [9]. However, both
techniques must be standardized before consistent com-
parisons can be made when interpreting retrospective/
prospective studies.
In conclusion, TYMS overexpression correlated with re-
sponse to pemetrexed and death, and a significant benefit
was observed in patients with low TYMS expression, sug-
gesting that this enzyme might be used as a predictive bio-
marker in advanced NSCLC patients.
Fig. 1 Design and optimization of the qPCR assay. a Primer region selection for TYMS target gene used for expression analysis. NCBI Reference Sequence
was NM_001071.2 (Homo sapiens thymidilate synthetase, mRNA). b Specificity for TYMS mRNA sequence was demonstrated in a 2 % agarose
gel electrophoresis loaded with 10 μl PCR products from 3 random FFPE samples. TYMS products are expected to be 95 bp long. DNA Molecular Weight
Marker XIII 50 bp ladder (Roche). c Primer efficiency for the TYMS qPCR assay. The efficiency of the primer pair was assessed by plotting the cycle threshold
value (Cp) at each concentration against the logarithm of the fold dilution of the sample. The slope of a linear-regression trend line is indicative of primer
efficiency. d Primer region selection for ATP5E reference gene. NCBI Reference Sequence was NM_006886.3 (Homo sapiens ATP synthase, H+ transporting,
mitochondrial F1 complex, epsilon subunit, mRNA). e Specificity for ATP5E mRNA sequence was demonstrated in a 2 % agarose gel electrophoresis loaded
with 10 μl PCR products from 3 random FFPE samples. ATP5E products are expected to be 101 bp long. f Primer efficiency for the ATP5E qPCR assay
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Methods
Patient samples
A single-institution retrospective analysis was carried out
including samples archived in the Fundacion Jimenez Diaz
Biobank (Madrid) from 62 consecutive patients who had
received clinical follow-up from. The study included
62 patients with stage IV NSCLC (49 adenocarcinomas, 7
NSCLC nos and 6 squamous-cell carcinomas). Sixteen pa-
tients received platins-pemetrexed as first-line treatment
for NSCLC and 46 received pemetrexed as monotherapy
in second and subsequent lines. Tissue microarrays were
constructed with 3 1.0-mm cores obtained from FFPE
tumor biopsies before treatment. Immunostaining was per-
formed to discriminate between histological subtypes. The
study was approved by the hospital ethics committee and
was conducted in accordance with institutional guidelines.
Ethics statement
The study was approved by the ethics committee of the
Fundacion Jimenez Diaz hospital (CEIC-FJD) in ac-
cordance with the Spanish Royal Legislative Decree
RD 223/2004.
Consent statement
Written informed consent for participation in the study
was obtained from all participants.
Gene expression analysis by qPCR
The level of TYMS gene expression was determined by a
quantitative RT-real time PCR assay on 5 × 10-μm sections
of the FFPE biopsies using ATP5E as a housekeeping gene.
Total RNA was isolated using the RNeasy FFPE kit
(Qiagen). Primers were designed according to the mRNA
sequences NM_00101071 for TYMS (and NM_006886.2,
and NM_001001977.1 for ATP5E. qPCRs were performed
using the LightCycler480 II system (Roche Applied Sci-
ence, Switzerland) for 45 cycles with the following sets
of primers: TYMS, 5′-CCTCTGCTGACAACCAAACG
(exon 1) and 5′-GAAGACAGCTCTTTAGCATTTG
(exon 2); ATP5E, 5′-CCGGCGTCTTGGCGATTC
(exon 1) and 5′-GATCTGGGAGTATCGGATG (exon 2).
Relative TYMS expression ratios were calculated using
the Pfaffl method [12], using the ATP5E levels as the ref-
erence sample. TYMS expression levels were normalized
to the calibrator levels (normal lung tissue) (Fig. 1). The
efficiencies of every primer pair were estimated by a
standard curve.
Statistical analysis
The primary end points were objective response rate,
time to progression (TTP), and overall survival (OS).
TTP was defined as the time from treatment to the start
of progression, censored at last contact. OS was defined
Table 1 Clinical-pathological correlations for TYMS gene expression in NSCLC patients treated with pemetrexed
Total TYMS high expression TYMS low expression
n n % n % P-value
Age (mean (range)) 57 (32–79) 54 (32–79) 66 (60–78) 1
Gender Male 40 26 65.0 14 35.0 0.419
Female 22 12 54.5 10 45.5
Smoking habit Current smoker 24 18 75.0 6 25.0 0.056
Former smoker 22 14 63.6 8 36.4
Never smoker 16 6 37.5 10 62.5
Histology Adenocarcinoma 49 27 55.1 22 44.9 0.071
NSCLC nos 7 7 100 0 0
Squamous cell carcinoma 6 4 66.7 2 33.3
ECOG performance status ECOG0 27 19 70.4 8 29.6 0.392
ECOG1 32 17 53.1 15 46.9
ECOG2 3 2 66.7 1 33.3
Line of treatment 1st line 16 9 56.3 7 43.8 0.661
2nd line 14 10 71.4 4 28.6
3rd, further lines 32 19 59.4 13 40.6
Response No 45 30 66.7 15 33.3 0.025
Yes 7 1 14.3 6 85.7
Not evaluatable 10 7 70.0 3 30.0
Progression No 24 4 16.7 20 83.3 0.003
Yes 38 34 89.5 4 10.5
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as the time elapsed from the date of initial diagnosis to
the date of death from any cause or the date of last
follow-up. Receiver operating characteristic (ROC) ana-
lysis was used to determine the optimal cutoff value
based on progression endpoint for TYMS. Survivals were
analyzed by the Kaplan-Meier method (median follow-
up, 75 months) and curves were compared by the log-
rank test. Multivariate analysis including continuous
quantitative and qualitative clinical-pathologic parameters
was done using the Cox proportional hazards model. All
statistical tests were conducted at the two-sided 0.05 level
of significance. This work was performed in accord-
ance with the Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK) guideline.
Statistical analysis was carried out using the IBM
SPSS, version 21.0.
Results
TYMS gene expression in advanced tumors
In order to assess the suitability of TYMS gene-expression
measurement as a predictive marker of pemetrexed sensi-
tivity in advanced NSCLC patients, we first quantitatively
evaluated the TYMS gene-expression levels in samples
from the 62 pemetrexed-treated patients in our series. Pa-
tient data were normalized against healthy lung-tissue
values. By performing a ROC curve analysis of TYMS ex-
pression against disease progression, we established a cut-
off value of 2.55. Interestingly, 38 patients (61 %) were
Fig. 2 a Significant clinical-pathological correlations for TYMS expression in NSCLC patients. With respect to the type of response, tumors were
categorized as either responding (CR, complete response or PR, partial response) or non-responding (SD, stable disease or PD, progressive disease).
b Close-to-significance correlations
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labeled as TYMS-overexpressing and 24 cases (39 %)
showed low expression.
TYMS overexpression is associated with disease
progression
The clinical characteristics of the patients are shown in
Table 1. TYMS gene-overexpression analysis was per-
formed in 62 cases for which complete clinical records
were available. This analysis showed significant correlation
with progression (P = 0.003) and response to pemetrexed
(P = 0.025) (Fig. 2a). We categorized the tumors as either
responding or non-responding. The non-responding group
showed significantly higher levels of TYMS expression as
compared to the responding group. TYMS overexpression
analysis also showed a tendency toward correlation
between overexpression smoking (P = 0.056) and histology
(P = 0.071) (Fig. 2b), but was not associated with gender,
performance status, or line of treatment.
Low TYMS expression levels predict delayed progression
in advanced cancers
We found that patients with a low level of TYMS gene
expression (cutoff < 2.55) had a significantly longer TTP
than those with a high level (Fig. 3). NSCLC patients
Fig. 3 TTP (a) and OS (b) in NSCLC patients. The blue line denotes patients with low TYMS gene expression; the red line indicates patients with
high TYMS expression
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with low TYMS expression levels showed a significant
benefit when treated with pemetrexed both in time to
progression (average TTP = 56 vs. 23 months, P = 0.001)
and in overall survival (average OS = 60 vs. 25 months,
P = 0.002) (Fig. 3). These data thus suggest that TYMS
expression level in advanced NSCLC tumors is inversely
correlated with response to pemetrexed.
Discussion
In the present study, we investigated the effects of TYMS
gene overexpression on the sensitivity of advanced cancer
cells to pemetrexed. Reliable predictive markers of benefi-
cial therapy can aid in determining the most appropriate
therapy for patients and minimize the negative effects of
certain treatment regimens in non-responsive patients.
TYMS gene expression was determined by qPCR gene
expression analysis in a series of NSCLC patients. Our
results confirm the overexpression of TYMS in this
population and suggest that assessment of TYMS gene-
expression levels by qPCR may be of predictive value
when assesing sensitivity to pemetrexed-based chemo-
therapy in NSCLC. There is an expanding corpus of re-
ports about TYMS expression levels in NSCLC patients,
some confirming that TYMS expression is significantly
increased in tumor cells but not in normal epithelial
cells [9, 13]. Recently, in accordance with the results
found in our series described here, 2 meta-analyses re-
ported that null or low expression of TYMS was associated
with higher objective response in NSCLC patients treated
with pemetrexed-containing chemotherapy [14, 15]. Of
note, objective response rates were significantly higher in
TYMS -/low expression patients than in TYMS +/high ex-
pression patients when examined by IHC. However, this
difference did not reach statistical significance in stud-
ies performed by RT-PCR [14], thus contrasting with
our results. Both of the aforementioned studies suggest
that TYMS may be a suitable marker of sensitivity to
pemetrexed-based chemotherapy in patients with
NSCLC, although one of them indicates that the prognos-
tic value of TYMS protein expression may need further
validation. In our case, TYMS overexpression correlated
significantly with progression and type of response. A
small number of studies have also addressed the relation-
ship between TYMS expression and effect of pemetrexed-
based chemotherapy, although reports about the prognos-
tic significance of TYMS expression in advanced NSCLC
are controversial [16]. Notably, most of them suggest that
elevated levels of TYMS expression are significantly asso-
ciated with reduced tumor responses and shorter survival
rates [6, 9, 17]. In addition, our data illustrated that treat-
ment with pemetrexed benefited patients with low TYMS
gene expression in terms of TTP. Although other studies
have suggested that TYMS expression holds potential as a
predictor of responsiveness to pemetrexed treatment in
advanced cancer patients [3, 6, 9, 18], prospective studies
are necessary to confirm these findings in NSCLC
patients.
Our study offers evidence in support of using qPCR to
determine TYMS mRNA expression as an alternative to
the standard evaluation of protein expression (i.e., IHC),
provided at least 80 % tumor cell content per sample is
achieved by laser capture microdissection. Although
most of the reported studies have used IHC to evaluate
TYMS abundance levels, and only a minority have used
qPCR, some meta-analyses have failed to find evidence of
heterogeneity between detection-method subgroups (ei-
ther IHC or qPCR) [14]. Moreover, another meta-
analysis reported that there was a significant correlation
between IHC and qPCR findings in the detection of
TYMS expression and their corresponding associations
with survival rates [3].
Conclusions
In conclusion, our study carried out using qPCR assay
reveals that the TYMS gene was predominantly overex-
pressed in these routine clinical samples, and that TYMS
overexpression correlated with reduced response to
pemetrexed-containing chemotherapy. In light of
these findings, TYMS gene expression might be used
as a predictive biomarker of sensitivity to pemetrexed-
based chemotherapy in advanced NSCLC patients. Fur-
ther prospective studies are ongoing in our institution to
validate the appropriateness of using TYMS in clinical de-
cision making.
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